SALARIUS PHARMACEUTICALS INC (SLRX) Stock Price & Overview
NASDAQ:SLRX • US79400X5032
Current stock price
The current stock price of SLRX is 0.84 USD. Today SLRX is up by 29.23%. In the past month the price increased by 1.2%. In the past year, price decreased by -96.42%.
SLRX Key Statistics
- Market Cap
- 4.922M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -39.18
- Dividend Yield
- N/A
SLRX Stock Performance
SLRX Stock Chart
SLRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SLRX. When comparing the yearly performance of all stocks, SLRX is a bad performer in the overall market: 99.58% of all stocks are doing better.
SLRX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SLRX. SLRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SLRX Earnings
SLRX Forecast & Estimates
SLRX Groups
Sector & Classification
SLRX Financial Highlights
Over the last trailing twelve months SLRX reported a non-GAAP Earnings per Share(EPS) of -39.18. The EPS increased by 68.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.08% | ||
| ROE | -117.81% | ||
| Debt/Equity | 0 |
SLRX Ownership
SLRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLRX
Company Profile
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
Company Info
IPO: 2015-01-29
SALARIUS PHARMACEUTICALS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS 77021 US
CEO: David J. Arthur
Employees: 2
Phone: 13467720346
SALARIUS PHARMACEUTICALS INC / SLRX FAQ
Can you describe the business of SALARIUS PHARMACEUTICALS INC?
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. The company is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
What is the current price of SLRX stock?
The current stock price of SLRX is 0.84 USD. The price increased by 29.23% in the last trading session.
Does SALARIUS PHARMACEUTICALS INC pay dividends?
SLRX does not pay a dividend.
How is the ChartMill rating for SALARIUS PHARMACEUTICALS INC?
SLRX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists SLRX stock?
SLRX stock is listed on the Nasdaq exchange.
What is SALARIUS PHARMACEUTICALS INC worth?
SALARIUS PHARMACEUTICALS INC (SLRX) has a market capitalization of 4.92M USD. This makes SLRX a Nano Cap stock.